Cugene Inc.
Clinical-stage biotechnology company based near Boston developing precision immunotherapies for cancer and autoimmune diseases. The organization focuses on protein engineering, molecular design of biologics (engineered cytokines, cell- or tissue-selective antibodies, and bispecifics with tumor-activatable masking), preclinical in vivo efficacy testing, and early-phase clinical development to evaluate safety, tolerability, PK/PD and biological activity.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Treg-selective long-acting IL-2 therapeutic (clinical-stage)
Precision-engineered IL-2 variant designed to selectively activate regulatory T cells while minimizing effector cell engagement; developed as a long-acting subcutaneous therapeutic to restore immune tolerance in autoimmune diseases; transitioned through Phase 1a healthy volunteer study and into Phase 1b patient studies.
Tumor-activable TIL-targeting bispecific immunotherapies (preclinical)
Bispecific and multi-mechanism biologics engineered to selectively engage tumor-reactive tumor-infiltrating lymphocytes, combining checkpoint inhibition and cytokine stimulation with tumor-activatable masking domains to localize activity and reduce systemic toxicity; reported complete regressions in multiple murine tumor models.
Treg-selective long-acting IL-2 therapeutic (clinical-stage)
Precision-engineered IL-2 variant designed to selectively activate regulatory T cells while minimizing effector cell engagement; developed as a long-acting subcutaneous therapeutic to restore immune tolerance in autoimmune diseases; transitioned through Phase 1a healthy volunteer study and into Phase 1b patient studies.
Tumor-activable TIL-targeting bispecific immunotherapies (preclinical)
Bispecific and multi-mechanism biologics engineered to selectively engage tumor-reactive tumor-infiltrating lymphocytes, combining checkpoint inhibition and cytokine stimulation with tumor-activatable masking domains to localize activity and reduce systemic toxicity; reported complete regressions in multiple murine tumor models.
Expertise Areas
- Precision immunoengineering
- Autoimmune therapeutics development
- Oncology immunotherapy
- Biologics discovery and engineering
Key Technologies
- Engineered cytokines (IL-2 muteins)
- Bispecific antibody therapeutics
- Pro-drug/masking domain technology
- Protein engineering
News & Updates
Presentation of preclinical data for a tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes and minimize peripheral activation using masking technology.
Progression of a Treg-selective long-acting IL-2 candidate into Phase 1b clinical studies enrolling patients with mild-to-moderate systemic lupus erythematosus to assess safety, tolerability, PK and PD.
Regulatory authorization to initiate a first-in-human subcutaneous study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers.
Announcement of an exclusive worldwide license option agreement for IL-2 muteins and related candidates with a pharmaceutical company to advance autoimmune disease therapeutics.
Unveiled preclinical results demonstrating robust anti-tumor efficacy through tumor-infiltrating lymphocyte targeting and cis-activation that reduced systemic toxicity and enhanced therapeutic window.
Oral presentation describing a long-acting Treg-selective IL-2 with high specificity and low toxicity for autoimmune disease applications.
Presentation of preclinical data for a tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes and minimize peripheral activation using masking technology.
Progression of a Treg-selective long-acting IL-2 candidate into Phase 1b clinical studies enrolling patients with mild-to-moderate systemic lupus erythematosus to assess safety, tolerability, PK and PD.
Regulatory authorization to initiate a first-in-human subcutaneous study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers.
Announcement of an exclusive worldwide license option agreement for IL-2 muteins and related candidates with a pharmaceutical company to advance autoimmune disease therapeutics.
Unveiled preclinical results demonstrating robust anti-tumor efficacy through tumor-infiltrating lymphocyte targeting and cis-activation that reduced systemic toxicity and enhanced therapeutic window.
Oral presentation describing a long-acting Treg-selective IL-2 with high specificity and low toxicity for autoimmune disease applications.